{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
21 CFR 334
(2018)
Source URL:
First approved in 2012
Source:
Bone Care by Evercarepharm Co., Ltd
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
B.S.C AMPUL by Cellcos Inc
(2013)
Source URL:
First approved in 2012
Source:
21 CFR 347
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2016)
Source URL:
First approved in 2012
Source:
Green Body by Evercarepharm Co., Ltd
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
U-max Wrinkle Serum by VS Shinbi Co., Ltd.
(2012)
Source URL:
First approved in 2012
Source:
U-max Wrinkle Serum by VS Shinbi Co., Ltd.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
First approved in 2012
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BOTANIC TWENTY HYPERCARE PLUMPING FORMULA by RITZY NOBLE CO., LTD.
(2018)
Source URL:
First approved in 2012
Source:
M006
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 347
(2017)
Source URL:
First approved in 2012
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2012)
Source URL:
First approved in 2012
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
First approved in 2012
Source:
JEUNCELL a drug for atopic dermatitis by Jeun Cell Ltd
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Deluqing by Shenzhen Deyintang Biotechnology Co., Ltd.
(2022)
Source URL:
First approved in 2012
Source:
DR. IASO by IASO Inc
Source URL:
Class:
STRUCTURALLY DIVERSE